Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CHYM vs WLTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHYM Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

CHYM Overall Winner 6-Pillar Tally: CHYM 6 – 0 WLTH Matrix Metrics: CHYM 9 – 1 WLTH

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over WLTH (WLTH) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHYM carries a Unified Composite Score of 33.1/100 (SELL) at $34.25 (30.9x Forward P/E, 19.3% operating margin), whereas WLTH carries 50.7/100 (HOLD) at $10.81 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While WLTH currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. CHYM 33.1/100 SELL), CHYM captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.3% vs. N/A operating margin) and revenue trajectory (+32.1% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHYM vs WLTH
CHYM NASDAQ Head-to-Head Winner
Chime Financial, Inc. Class A Common Stock
Finance Services
$34.25
+2.09% 1D
Market Cap $12.7B
TTM Revenue $14.3B
Forward P/E 30.9x
Beta / 30D Vol 1.44β · 37% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 15.0 Fund 33.0 Flow 57.0 Mom 30.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 74
RSI-14: 73.7 · SMA20: $30.53 · SMA50: $29.95
WLTH US Equity
WLTH
Institutional Equity
$10.81
+0.84% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.97β · 53% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.8% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $10.72 · SMA50: $10.50

6-Pillar Scorecard Institutional Category Breakdown (CHYM 6 – 0 WLTH)

Columns: Metric · CHYM · WLTH
1. Valuation Multiples CHYM
Forward P/E 30.9x N/M
Trailing P/E 29.0x N/M
PEG Ratio N/M N/M
EV / Revenue 0.7x N/M
2. Growth & Scale CHYM
Revenue Growth (YoY) +32.1% N/A
Earnings Growth (YoY) -33.8% N/A
TTM Revenue (USD) $14.3B N/A
Market Cap $12.7B N/A
3. Profitability & Quality CHYM
Gross Margin 89.4% N/A
Operating Margin 19.3% N/A
Net Profit Margin 3.0% N/A
Return on Equity (ROE) 5.4% N/A
4. Balance Sheet & Cash Flow CHYM
Cash Generation (TTM) $2.27B N/A
Cash Flow Margin 15.8% N/A
Net Cash / Leverage $2.77B Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CHYM
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 50.0% (15th %ile) N/A (N/A)
Put/Call OI Skew 0.22x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat CHYM
OpEx & R&D Intensity 70.1% of Rev ($10.1B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHYM (9) vs WLTH (1)
Institutional Metric CHYM WLTH Criterion Row Edge
Market Capitalization
Scale
$12.7B N/A Larger Scale CHYM
Trailing P/E Ratio
Valuation
29.0x N/M Lower Multiple CHYM
Forward P/E Ratio
Valuation
30.9x N/M Lower Multiple CHYM
Revenue Growth (YoY)
Growth
+32.1% N/A Higher Growth CHYM
Operating Margin (TTM)
Profitability
19.3% N/A Higher Margin CHYM
Net Profit Margin
Profitability
3.0% N/A Higher Margin CHYM
Return on Equity (ROE)
Capital Efficiency
5.4% N/A Higher ROE CHYM
52-Week Range Position
Momentum
93% ($16–$36) 47% ($7–$15) Stronger Trend CHYM
Beta / 30D Volatility
Risk Regime
1.44β · 37% Vol 0.97β · 53% Vol Lower Realized Risk CHYM
Unified Institutional Score
Composite Signal
33.1 / 100 (SELL) 50.7 / 100 (HOLD) Higher Composite WLTH
Trailing 12M Revenue (USD)
Operating Scale
$14.3B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.27B ($2.77B Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHYM +13.75 pp
CHYM: +15.44% · WLTH: +1.69%
3M Horizon WLTH +13.32 pp
CHYM: +7.33% · WLTH: +20.65%
6M Horizon CHYM +105.3 pp
CHYM: +95.16% · WLTH: -10.14%
1Y Horizon CHYM +53.58 pp
CHYM: +30.6% · WLTH: -22.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHYM vs WLTH. Trailing 12-month operating profitability (CHYM 19.3% vs WLTH N/A) and valuation multiples (CHYM 30.9x vs WLTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CHYM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.3B
Gross Margin89.4%
Op. Margin19.3%
ROE / Fwd P/E5.4% · 30.9x
WLTH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHYM CONSOLIDATION
48d in phase · OBV ACCUMULATION
Current IV 50.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CHYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WLTH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WLTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHYM Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $12.7B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 70.1% of Rev ($10.1B)
90D Engineering Disclosures 0 Published
WLTH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CHYM vs WLTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over WLTH (WLTH) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHYM carries a Unified Composite Score of 33.1/100 (SELL) at $34.25 (30.9x Forward P/E, 19.3% operating margin), whereas WLTH carries 50.7/100 (HOLD) at $10.81 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While WLTH currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. CHYM 33.1/100 SELL), CHYM captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.3% vs. N/A operating margin) and revenue trajectory (+32.1% vs. N/A YoY).

CHYM leads the Growth & Scale pillar: CHYM posts +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin), compared with WLTH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CHYM generates $14.3B in USD-normalized revenue versus N/A for WLTH. In operating R&D and SG&A reinvestment, CHYM deploys 70.1% of Rev ($10.1B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for WLTH.

CHYM screens cheaper on headline valuation multiples. CHYM trades at 30.9x Forward P/E, 29.0x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (15.8% FCF margin), whereas WLTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHYM (5.4% ROE) versus WLTH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CHYM carries 50.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.44β · 37% Vol realized risk). By comparison, WLTH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.